1047 related articles for article (PubMed ID: 22939820)
1. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
2. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
3. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
4. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
5. Central kynurenine pathway shift with age in women.
de Bie J; Guest J; Guillemin GJ; Grant R
J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Chen Y; Meininger V; Guillemin GJ
Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):32-9. PubMed ID: 20021336
[TBL] [Abstract][Full Text] [Related]
7. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
[TBL] [Abstract][Full Text] [Related]
8. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
11. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ
Neuropharmacology; 2017 Jan; 112(Pt B):346-364. PubMed ID: 27265569
[TBL] [Abstract][Full Text] [Related]
12. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Németh H; Toldi J; Vécsei L
J Neural Transm Suppl; 2006; (70):285-304. PubMed ID: 17017544
[TBL] [Abstract][Full Text] [Related]
13. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
14. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
15. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
16. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
17. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
Schwarcz R; Pellicciari R
J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
[TBL] [Abstract][Full Text] [Related]
19. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Szabó N; Kincses ZT; Toldi J; Vécsei L
J Neurol Sci; 2011 Nov; 310(1-2):256-60. PubMed ID: 21824629
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]